quarta-feira, 4 de novembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 18, 2026

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease

View original at globenewswire.com
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease - First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of commo…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Preclinical studies support the potential of SER-252 to provide continuous dopaminergic stimulation without skin reactions

    60% confidence

  • Company remains laser-focused on generating the clinical data that will demonstrate the potential of SER-252 to transform the treatment of advanced Parkinson's disease

    60% confidence

  • Serina expects that a blinded review of safety and tolerability data from Cohort 1 will support advancement to Cohort 2 in the third quarter of 2026

    60% confidence

  • Serina's POZ technology has the potential to improve the safety and pharmacokinetic profile of drugs that have historically been constrained by side effects, opening the door to a portfolio of optimized medicines

    60% confidence

  • This financing positions Serina to execute on the most value-creating milestones in the Company's history with the first patient dosed in registrational trial and a clear 505(b)(2) pathway aligned with the FDA

    60% confidence

  • Continuous dopaminergic stimulation has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson's disease

    60% confidence

  • With recent FDA feedback confirming a clear and capital-efficient 505(b)(2) regulatory pathway for SER-252, the Company now has a well-defined route toward registration

    60% confidence

  • The Company is targeting topline results from the single-ascending dose (SAD) study arm in the first half of 2027

    60% confidence

  • By using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood

    60% confidence

  • The most compelling opportunities are those that others initially overlook but that ultimately unlock significant therapeutic value

    60% confidence

  • SER-252 has the potential to become a best-in-class therapy for the approximately 250,000 advanced Parkinson's patients in the U.S. and Europe whose symptoms remain inadequately controlled by current treatments

    60% confidence

  • The milestone-gated structure of this financing aligns capital deployment with trial progress and preserves flexibility to access additional strategic and non-dilutive funding

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
AI Moves Into Devices, Security and Platforms: Physical AI Data, On-Device Compute and Agent Governance Drive a Late-October Product Wave
In late October 2026, vendors across hardware, enterprise software and security launched products built around AI moving out of the cloud and into devices, workflows and physical systems. Examples include NVIDIA RTX Spark laptops with Adobe, ASUS and Windows support for local and hybrid AI, and Harvest Praxis and Encord on embodied or physical AI. Enterprise software and security vendors (Salesforce–Braze, Fortinet, ServiceNow, Cisco, Intuit) are consolidating AI-driven customer data, adding inline AI security and agent governance, and embedding AI in financial and accounting workflows. The finance link is indirect: it rests on M&A, fintech-adjacent AI tooling and the capital flowing into physical AI. No regulatory driver appears in the facts.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,548 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease — Source | Via News | pt.VIA.NEWS